Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
I know, that buy dildos online is cheaper.
Popular Articles

Shire Presented Results Of A New Database Analysis On Lialda(R) (Mesalamine) And Other 5-ASAs For Ulcerative Colitis At Digestive Disease Week
Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, presented the results of a 5-aminosalicylic acid (5-ASA) persistency analysis entitled, "Twelve-month Persistence with 5-aminosalicylic Acid Therapy: Results from a Large Pharmacy Database," at Digestive Disease Week, on May 31, 2009. Results showed that after 12 months of therapy for continuing patients, 20 percent of Lialda patients were continually persistent, 9 percent of Asacol(R) (mesalamine) patients, 7 percent (250mg) and 10 percent (500mg) of Pentasa(R) (mesalamine) patients, 10 percent of balsalazide [combined results from generic balsalazide disodium and Colazal(R) (balsalazide disodium)] patients, and 10 percent (500mg) of Dipentum(R) (olsalazine sodium) patients were persistent. Continually persistent patients were defined as those who refilled their prescription within a period of up to twice the duration of the prescription that preceded the refill. Lialda is an FDA-approved, once-daily oral medication for the induction of remission in patients with active, mild to moderate ulcerative colitis (UC). Safety and effectiveness of Lialda beyond eight weeks have not been established.
drugs without prescription
Delaware HIV/AIDS Organization Forced To Close After 28 Years
A Delaware-based organization that has provided HIV prevention, outreach, education and other services for the past 28 years will be closing due to lack of funding, the Bethany Beach Wave reports. The Sussex County AIDS Committee (SCAC) also provided financial assistance, transportation services and assistance with medical appointments to people living with HIV/AIDS from as far as Philadelphia, according to the Wave. SCAC was funded by both private and government funding. "We just ran out of money," Curt Barrows, president of the SCAC board, said. CAMP Rehoboth, another local organization, said it will step in to assist SCAC clients (Shockley, Bethany Beach Wave, 6/18).
News of the day
Recent Releases: New Res On HIV Testing In The U.S. Available, Nationwide HIV Campaign Announced
The Kaiser Family Foundation, ahead of National HIV Testing Day on Saturday, has released new and updated informational res on HIV testing in the U.S., including a fact sheet that provides HIV testing statistics, policies and CDC recommendations. In addition, the Foundation released two survey briefs, which examine the public"s attitudes, experiences and knowledge related to HIV testing, one of which focuses on black residents. The briefs are based on the 2009 Survey of Americans on HIV/AIDS released this spring. Information regarding HIV testing by state also is available through statehealthfacts.org (Kaiser Family Foundation release, 6/24).
Sexual Health

Lawsuit Filed Over Gene Patent

A group of cancer patients, genetic researchers and professional pathologist organizations has filed a lawsuit against Myriad Genetics and the U.S. Patent Office over the patent of two genes associated with an increased risk of breast and ovarian cancers, the New York Times reports. According to the Times, the government more than 10 years ago granted Myriad the patent on the BRCA1 and BRCA2 genes, as well as the company"s genetic test that measures a patient"s risk for the cancers.The lawsuit was filed by the American Civil Liberties Union and is believed to be the first of its kind, the Times reports. The lawsuit challenges the decision to grant patents on genes to Myriad and companies like it. The plaintiffs say that patents on genes restrict medical and research efforts, while companies like Myriad have said that the patent system supports innovation by giving them a temporary monopoly after they make a discovery, thereby rewarding prior investment in research and development.Wendy Chung, the director of clinical genetics at Columbia University and a plaintiff in the case, said, "With a sole provider, there"s mediocrity." The plaintiffs say that BRCA testing would improve with market competition. Furthermore, some plaintiffs argue that certain natural materials cannot be patented. Jan Nowak, president of the Association for Molecular Pathology and a plaintiff in the case, said, "You can"t patent my DNA, any more than you can patent my right arm, or patent my blood."To date, two government panels, including the National Research Council, found no evidence that gene patents result in significant impediments to research or medical care (Schwartz, New York Times, 5/13). Reprinted with kind permission from http://www.nationalpartnership.org. You can view the entire Daily Women"s Health Policy Report, search the archives, or sign up for email delivery here. The Daily Women"s Health Policy Report is a free service of the National Partnership for Women & Families, published by The Advisory Board Company. © 2009 The Advisory Board Company. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009